Somatostatinoma Syndrome: Biochemical, Morphologic and Clinical Features

G. J. Krejs, L. Orci, J. M. Conlon, M. Ravazzola, G. R. Davis, Philip Raskin, S. M. Collins, D. M. McCarthy, D. Baetens, A. Rubenstein, T. A. Aldor, Roger H Unger

Research output: Contribution to journalArticle

278 Scopus citations

Abstract

Diabetes mellitus, steatorrhea, cholelithiasis and a tumor distorting the duodenum prompted a work-up for somatostatinoma in a 52-year-old man. The responses of pancreatic B-cells but not of A-cells to nutrient stimuli were inhibited, and growth-hormone release was suppressed, suggesting somatostatin resistance in some target tissues. Plasma somatostatin-like immunoreactivity ranged from 9000 to 13,000 pg per milliliter (normal: 88±8, mean ± S.E.M.) and was distributed in four molecular forms, including free somatostatin. The primary tumor contained 5 μg of somatostatin-like immunoreactivity per milligram of wet tissue, distributed in three of the molecular forms noted in plasma. Plasma calcitonin was also elevated (4650 pg per milliliter; normal: <120). Immunocytochemical studies showed that cells of the primary tumor contained somatostatin and calcitonin but no other peptide hormones. Only somatostatin was present in the metastases. Somatostatin was localized electron microscopically in all secretory granules, irrespective of size and shape, whereas calcitonin was present only within a single subpopulation of small granules in the same cells. (N Engl J Med 301:285–292, 1979) IN 1977, two cases of pancreatic somatostatinoma were reported by Larsson1 and Ganda2 and their colleagues. On the basis of these reports and the known pharmacologic effects of somatostatin, a tentative description of the somatostatinoma syndrome was proposed.3 However, in the first two patients the tumor was found incidentally at the time of cholecystectomy, and a complete preoperative work-up had not been performed. Three other patients with malignant islet-cell tumors that contained somatostatin have been described in brief communications.4 5 6 In addition to somatostatin, one of these tumors contained ACTH,4 and one calcitonin.6 In this case report, the diagnosis of somatostatinoma.

Original languageEnglish (US)
Pages (from-to)285-292
Number of pages8
JournalNew England Journal of Medicine
Volume301
Issue number6
DOIs
StatePublished - Aug 9 1979

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Somatostatinoma Syndrome: Biochemical, Morphologic and Clinical Features'. Together they form a unique fingerprint.

  • Cite this

    Krejs, G. J., Orci, L., Conlon, J. M., Ravazzola, M., Davis, G. R., Raskin, P., Collins, S. M., McCarthy, D. M., Baetens, D., Rubenstein, A., Aldor, T. A., & Unger, R. H. (1979). Somatostatinoma Syndrome: Biochemical, Morphologic and Clinical Features. New England Journal of Medicine, 301(6), 285-292. https://doi.org/10.1056/NEJM197908093010601